Idera Pharma Appoints New CMO
This article was originally published in Scrip
Idera Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for cancer and rare diseases, has named Dr. Joanna Horobin senior vice president and chief medical officer. Horobin was most recently chief medical officer of Verastem Inc. and previously served as CEO of Syndax Pharmaceuticals. Prior to her positions at Verastem and Syndax, she held several roles of increasing responsibility at global pharmaceutical corporations such as Rhône-Poulenc Rorer (now Sanofi), where she spearheaded the global oncology business unit’s launches of Taxotere (docetaxel) in breast cancer and Campto/Camptosar (CPT11) for colorectal cancer. Horobin's appointment with Idera will commence on November 30, 2015.